loader image
Close
A New Paradigm for Treating Chronic Inflammatory Disease A New Paradigm for Treating Chronic Inflammatory Disease

Archives

Monthly Archive for: "October, 2019"
0
By admin
In news archive
Posted October 28, 2019

FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company’s novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).

View Press Release

READ MORE
 FDA Orphan Drug Designation Granted
0
By admin
In news archive
Posted October 28, 2019

FDA Orphan Drug Designation Granted

The orphan drug designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market exclusivity. Link to Press Release

READ MORE
Stay Updated
Navigation
  • Home
  • COVID-19
  • News Archive
  • Psoriasis
  • Contact Us
Contact Us
  • 610 Old York Rd, Suite 400, Jenkintown, Pennsylvania 19046, United States

  • 267-584-1080
  • info@sfatherapeutics.com
© 2020 sfatherapeutics. All rights reserved.
SFAtx
  • Home
  • About Us
    • Management Team and Founders
    • Scientific Advisory Board
    • Business Advisory Team
  • Our Science
  • Current Focus and Pipeline
  • Clinical Trials
    • COVID-19
    • Psoriasis
  • News
    • News Archive
  • Investors
  • Contact Us